Showing results (271-280 of 392) with videos related to
Sort By:
Pageof 40
Leukemia Research|March 26, 2015
Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemiaMark C Lanasa, Leslie Andritsos, Jennifer R Brown, et al.Genes, Chromosomes & Cancer|February 26, 2022
T-cell prolymphocytic leukemia is associated with deregulation of oncogenic microRNAs on transcriptional and epigenetic levelPaurnima Patil, Sina Hillebrecht, Emil Chteinberg, et al.European Journal of Haematology|December 9, 2015
Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemiaChristian Maurer, Natali Pflug, Jasmin Bahlo, et al.Leukemia|June 2, 2025
NOTCH1 signaling is dysregulated by loss of the deubiquitinase USP28 with del(11q), uncovering USP28 inhibition as novel therapeutic target in CLLAlena Sophie Ehrmann, Miguel Quijada-Álamo, Viola Close, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2012
Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemiaRainer Claus, David M Lucas, Stephan Stilgenbauer, et al.Blood Advances|January 30, 2024
Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemiaStephan Stilgenbauer, Eugen Tausch, Andrew W Roberts, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2019
Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly TrialHanneke C Kluin-Nelemans, Eva Hoster, Olivier Hermine, et al.Molecular Systems Biology|May 24, 2019
Linking aberrant chromatin features in chronic lymphocytic leukemia to transcription factor networksJan-Philipp Mallm, Murat Iskar, Naveed Ishaque, et al.Cell Death & Disease|July 31, 2019
Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signalingFelix Seyfried, Salih Demir, Rebecca Louise Hörl, et al.Blood|February 2, 2022
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemiaHenriette Huber, Simone Edenhofer, Julia von Tresckow, et al.Pageof 40